01Identity
What is it?
Products contain a specified botulinum neurotoxin type with product-specific excipients and biological potency units; preparations are not automatically equivalent.
Botulinum Toxin Treatment · Aesthetic Medicine · Istanbul
Botulinum Toxin Treatment · Aesthetic Medicine · Istanbul
Botulinum Toxin Treatment
Botulinum toxin is a prescription biological medicine, not a generic unit-based commodity. Toxin type, manufacturer, formulation, potency assay, authorised indication and target muscle must be identified for the exact product.
Units from different botulinum toxin products cannot be compared or converted as if equivalent. This page does not publish a dose, dilution, point map or personal muscle plan.
Quick Orientation
Identity · composition · preparation · route
The treatment name is only the start of the medical description.
A responsible discussion identifies the exact preparation or device, how it was made, where it is intended to act and which clinical question is being assessed.
02Production
How is it prepared?
Manufacturing strain, purification, formulation, potency assay, vial presentation, storage and product-specific reconstitution define the medicine.
03Route
How does it reach tissue?
The labelled route is linked to a defined muscle or other target tissue. Unintended spread or exposure to adjacent structures can alter function.
04Target
What is the clinical target?
A specific pattern of muscle activity or authorised medical indication is assessed, with baseline movement and function documented before treatment.
Method Boundary
A product-specific prescription biological medicine
Toxin type, potency assay and authorised indication cannot be separated.
The intended role, product identity and target tissue stay visible so unlike procedures are not presented as one interchangeable class.
What may be considered
- Evaluate one authorised toxin product for one defined indication
- Link the treatment aim to observed muscle activity and anatomy
- Document baseline asymmetry, function and a review point
- Withhold or stop treatment when risk or uncertainty is excessive
What must not be inferred
- Convert units between different toxin products
- Treat every facial line as a muscle problem
- Ignore baseline weakness, asymmetry or neuromuscular disease
- Guarantee symmetry, lifting, duration or a fixed response
An unidentified product, unclear authorised indication or inability to assess the relevant muscle and neighbouring function is a reason not to treat.
Medical Suitability
Clinical question before method selection
Five checks precede any personal decision.
Expression and resting tone, asymmetry, previous toxin exposure, medicines, neuromuscular risk and the exact product are reviewed in person.
- 01
Define the indication
The intended change is linked to a product-specific authorised use or clearly disclosed off-label context.
- 02
Examine movement
Target and compensating muscles, eyelid or brow position, smile, swallowing and baseline asymmetry are assessed.
- 03
Verify the product
Toxin type, manufacturer, batch, storage, potency units and product-specific handling are checked.
- 04
Review health factors
Neuromuscular disease, infection, swallowing or breathing problems, interacting medicines, pregnancy and breastfeeding require assessment.
- 05
Compare alternatives
Observation, skin care, filler, another procedure or no treatment may better fit the clinical question.
Product and Treatment Path
Traceability without a public injection recipe
The product and potency assay stay attached to every unit.
Storage, reconstitution and biological potency are product-specific. A unit value cannot be copied from one preparation to another.
01Product
Toxin and vial identity
The exact biological medicine, batch, expiry, storage and licensed indication are verified.
- Name toxin type and manufacturer
- Retain vial and batch details
- Check indication and jurisdiction
02Preparation
Product-specific handling
Only the selected product information can guide storage and reconstitution; no cross-brand conversion is used.
- Follow the exact label
- Do not convert units
- Maintain sterile handling
03Anatomy
Target function and follow-up
Baseline movement, neighbouring function and the intended endpoint are recorded without publishing a point map.
- Document muscle function
- Record treated indication
- Set early and later review
No personal product, dose, unit count, dilution, muscle selection, injection point, needle or timing protocol is provided on this page.
Evidence and Limits
Read the data at product and indication level
Efficacy and safety are tied to product, indication and dose studied.
Regulatory trials and labels apply to a defined toxin preparation, muscle pattern and endpoint. Results cannot be converted between brands or extrapolated to every use.
Match the toxin product
One preparation's units, trial results and adverse events do not establish equivalence with another.
Match the indication
Evidence for one authorised facial area or medical condition cannot validate an unrelated target.
Keep function visible
A line-rating endpoint does not capture every effect on expression, eyelid, brow, smile or swallowing.
Read rare risks
Post-marketing reports and boxed warnings remain relevant even when common cosmetic reactions are mild.
A product-specific trial does not justify cross-brand units, unlisted indications, a fixed schedule or a predictable personal duration.
Individual Plan
One indication · one traceable intervention · one review point
A plan begins with baseline function, not a unit number.
The indication, exact product, muscle activity, asymmetry, adjacent function, alternatives and stop criteria are documented first.
Record movement
Standard expressions and resting position establish baseline activity and asymmetry.
Verify product and use
Toxin type, batch, licensed indication and any off-label context remain visible.
Protect function
The clinical aim is balanced against eyelid, brow, smile, speech, swallowing and breathing considerations.
Avoid early escalation
The response is reviewed at an appropriate time; early repeat dosing is not automatic.
Course and Follow-Up
Expected reaction · adverse effect · clinical endpoint
Effect, asymmetry and adverse weakness may appear on different timelines.
Injection-site reactions are recorded first. Muscle effect develops later and must be reviewed with function, not only appearance.
- 01Treatment day
Record the medicine
Product, batch, indication, region and baseline function remain traceable.
- 02Early review
Watch local function
Ptosis, diplopia, dry eye, marked asymmetry or unexpected weakness requires clinical review.
- 03Clinical review
Assess the intended target
Movement and the defined clinical endpoint are compared after the response has developed.
- 04Decision
Apply the stop rule
Swallowing, speech or breathing symptoms, significant weakness or an unacceptable functional change prevents routine repetition.
Risks and Alternatives
Material, anatomy and route shape risk
Local weakness and distant toxin effects must both be discussed.
Risk depends on the product, indication, anatomy, baseline neuromuscular function, medicines and individual susceptibility.
01Local
Local effects
Pain, bruising, headache, dry eye, eyelid or brow change, asymmetry and unwanted muscle weakness may occur.
02Systemic
Spread of effect
Generalised weakness, double vision, voice change, difficulty swallowing or breathing can occur and may be life-threatening.
03Assessment
Suitability limits
Infection, hypersensitivity, neuromuscular disorders, interacting medicines, pregnancy and breastfeeding require product-specific review.
04Decision
Withhold or stop
Treatment is withheld or stopped when the indication, consent, safety controls or follow-up cannot support a proportionate plan.
New swallowing, speech or breathing difficulty, generalised weakness or significant visual symptoms requires immediate local medical assessment. Alternatives may include observation, skin care, a filler or device-based option for a different tissue target, or no treatment.
Istanbul and Follow-Up
A treatment decision must remain reviewable after travel
Assessment, product records and a local safety route travel together.
International care is not reduced to a treatment day. The in-person examination, exact intervention, early review and later endpoint are connected before departure.
01Before travel
Organise the question
History, previous procedures and the specific botulinum toxin treatment question prepare the visit without confirming suitability.
02In Istanbul
Examine in person
Anatomy, tissue, active disease, product or device status, risks and alternatives are reviewed together.
03Treatment day
Keep exact records
Product or device identity, batch where relevant, treated region, route and observations remain traceable.
04After return
Arrange review
Expected reactions, stop criteria, local medical access and the later clinical endpoint are agreed before return travel.
The Doctor Aslan Approach
Product-specific, anatomy-led and reversible in decision-making
The clinical question begins with movement and function.
Product identity, authorised indication and muscle anatomy are reviewed before units are discussed. The aim is not a frozen or guaranteed expression.
Identify the toxin
Product, batch and potency assay remain attached to the decision.
Map function clinically
Baseline movement and compensating muscles are assessed in person.
Keep units product-specific
No conversion or dose borrowing occurs between brands.
Review before repeating
Function, adverse effects and the intended endpoint guide any later decision.
Medical responsibility: Dr İsmail AslanMedical review: 24 August 2026General patient information about botulinum toxin treatment; no personal protocol or outcome guarantee
Frequently Asked Questions
Short and clear
Questions commonly asked before a decision.
These answers provide general orientation and do not replace personal diagnosis or treatment planning.
01What is Botulinum Toxin Treatment?+
Botulinum Toxin Treatment is described on this page as one defined clinical route. Its role, limits and possible alternatives are considered together rather than treating the method name as a personal recommendation.
02Who may be assessed for Botulinum Toxin Treatment?+
Suitability depends on the medical question, history, examination, the exact product or device where relevant, realistic aims and an individual benefit–risk assessment.
03What remains undecided after an online review?+
Diagnosis, definitive suitability, the treatment protocol, product, dose or device settings, expected response and the option not to proceed remain subject to personal medical assessment.
04How are treatment and follow-up in Istanbul planned?+
The in-person examination remains the decision point. Expected early reactions, warning signs, the direct contact route, return travel and access to appropriate local medical care are discussed before treatment.
Next Step
Name the product · assess movement · protect function